Close Menu
May 26, 2021
Sponsored by
Lexogen

CaTCH it if you can! CRISPRa-based Exploration of Therapy Resistant Cell Clones

Genome Webinar

Scientist,
Research Institute of Molecular Pathology

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma. While founding clones are often extremely rare in a starting population, their isolation and characterization hold unique potential for understanding disease processes, uncovering novel biomarkers, and developing therapeutic concepts. 

In this webinar, Christian Umkehrer of Vienna’s Research Institute of Molecular Pathology describes the development and application of CaTCH (CRISPRa Tracing of Clones in Heterogeneous Cell Populations), which combines precise mapping of the lineage history of millions of cells with the ability to isolate any given clone alive from a complex population based on genetic barcodes. 

CaTCH enables the retrospective isolation and analysis of founding clones from heterogeneous cell populations prior to evolutionary selection. The approach uses QuantSeq 3’ mRNA-Seq to characterize the isolated clones by efficiently profiling gene expression.

In his presentation Christian Umkehrer will explain how CaTCH can:

  • be used to trace and isolate therapy-resistant clones from complex cancer cell populations in vitro.
  • be applied to in vivo studies by investigating the origins of resistance to clinically relevant RAF/MEK inhibition in an immunocompetent melanoma mouse model.
  • address further fundamental questions in basic and translational research (e.g., how cell identity states and trajectories are determined in therapy resistance, metastasis formation, or somatic cell re-programming).
Sponsored by
Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

May
26
Sponsored by
Lexogen

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.